Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.